clomipramine has been researched along with Agoraphobia in 32 studies
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Blunted neuroendocrine and physiological responses to the selective 5-HT(1A) receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA)." | 9.10 | 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Opitz, M; Pekrun, G; Rüther, E; Wedekind, D, 2003) |
| "This 12-week, placebo-controlled study was carried out to compare the relative efficacy of paroxetine, clomipramine, and cognitive therapy in the treatment of DSM-III-R-defined panic disorder with or without agoraphobia." | 9.09 | Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. ( Bakker, A; Spinhoven, P; van Balkom, AJ; van Dyck, R, 1999) |
| "Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment." | 9.08 | Clomipramine treatment of panic disorder: pros and cons. ( Campeas, R; Coplan, JD; Fallon, BA; Fyer, AJ; Gorman, JM; Klein, DF; Leibowitz, MR; Papp, LA; Schneier, FR, 1997) |
| "Forty-six outpatients suffering from moderate to severe panic disorder with or without agoraphobia (DSM-III-R criteria) were randomly assigned to a 10-week treatment protocol of regular aerobic exercise (running), clomipramine (112." | 9.08 | Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Rüther, E, 1998) |
| "Among 79 volunteer, unpaid, family doctor-referred psychiatric out patients with DSM III-R panic disorder, with and without agoraphobia, 66 completed a six week placebo-controlled trial of lofepramine versus clomipramine and 57 survivors were followed up for 6 months." | 9.07 | The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. ( Brophy, J; Fahy, TJ; O'Rourke, D; Schazmann, W; Sciascia, S, 1992) |
| "Seventeen outpatients with panic anxiety and agoraphobia were treated with a low, flexible dose of clomipramine in an 8-week open trial." | 9.06 | Panic attacks and agoraphobia: low dose clomipramine treatment. ( Codner, S; Cohen, L; Gladic, D; Gloger, S; Grunhaus, L; O'Ryan, F, 1989) |
| "A double-blind comparative study of clomipramine and fluvoxamine was performed in 50 patients suffering from anxiety disorders (DSM-III)." | 9.06 | Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. ( den Boer, JA; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "A double-blind placebo-controlled study of 5-HTP and clomipramine was carried out on 45 patients suffering from anxiety disorders (DSM-III)." | 9.06 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "A multi-centre, double-blind trial was carried out in general practice to compare the effectiveness and tolerability of clomipramine and diazepam in patients with agoraphobia or social phobia." | 9.05 | Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. ( Allsopp, LF; Cooper, GL; Poole, PH, 1984) |
| "In a large, open, multicentre trial, conducted in general practice, 765 patients suffering from agoraphobia or social phobias were treated with clomipramine (Anafranil, Geigy Pharmaceuticals)." | 7.65 | A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. ( Beaumont, G, 1977) |
| "This study investigated the chronic use (6." | 5.31 | Memory performance in panic disorder patients after chronic use of clomipramine. ( Artes, R; de Carvalho, SC; Gorenstein, C; Marcourakis, T, 2002) |
| "Blunted neuroendocrine and physiological responses to the selective 5-HT(1A) receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA)." | 5.10 | 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Opitz, M; Pekrun, G; Rüther, E; Wedekind, D, 2003) |
| "This 12-week, placebo-controlled study was carried out to compare the relative efficacy of paroxetine, clomipramine, and cognitive therapy in the treatment of DSM-III-R-defined panic disorder with or without agoraphobia." | 5.09 | Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. ( Bakker, A; Spinhoven, P; van Balkom, AJ; van Dyck, R, 1999) |
| "Patients with Panic disorder (DSM-IV) were randomly assigned to three treatment modalities: running (n=45), clomipramine (n=15) or placebo (n=15)." | 5.09 | The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Pralle, L; Rüther, E, 2000) |
| "Forty-seven patients meeting DSM-III-R criteria for panic disorder with agoraphobia (PAG) were assessed by the Minnesota Multiphasic Personality Inventory (MMPI) at baseline and after 8 weeks of treatment with imipramine, clomipramine and placebo." | 5.08 | Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. ( Gentil, V; Gorenstein, C; Ito, LM; Miyakawa, E, 1995) |
| "Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment." | 5.08 | Clomipramine treatment of panic disorder: pros and cons. ( Campeas, R; Coplan, JD; Fallon, BA; Fyer, AJ; Gorman, JM; Klein, DF; Leibowitz, MR; Papp, LA; Schneier, FR, 1997) |
| "Forty-six outpatients suffering from moderate to severe panic disorder with or without agoraphobia (DSM-III-R criteria) were randomly assigned to a 10-week treatment protocol of regular aerobic exercise (running), clomipramine (112." | 5.08 | Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. ( Bandelow, B; Bartmann, U; Broocks, A; George, A; Hillmer-Vogel, U; Meyer, T; Pekrun, G; Rüther, E, 1998) |
| "Endurance capacity was determined by bicycle spiroergometry in patients with panic disorder before (n = 38) and after (n = 10) a 10 week running program and compared to untrained healthy control subjects carrying out the same training (n = 11) and patients receiving clomipramine drug therapy (n = 7) or placebo (n = 7)." | 5.08 | Endurance training in panic patients: spiroergometric and clinical effects. ( Bandelow, B; Broocks, A; Hillmer-Vogel, U; Meyer, T; Rüther, E, 1998) |
| "Eighteen patients with panic disorder with agoraphobia who had not responded to previous inpatient behavioral treatment were recruited to a 12-week, placebo-controlled, double-blind crossover study of clomipramine, at top doses of 150 mg/day for 3 weeks." | 5.07 | Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. ( Bille, H; Due-Madsen, J; Gude, T; Hoffart, A; Lande, B; Torgersen, S, 1993) |
| " This paper reports a randomized, double-blind, 8-week trial in which the efficacy and safety of brofaromine was compared to clomipramine in patients with panic disorder with or without agoraphobia." | 5.07 | Reversible monoamine oxidase-A inhibitors in panic disorder. ( Bakish, D; Bowen, R; D'Souza, J; Saxena, BM, 1993) |
| "Among 79 volunteer, unpaid, family doctor-referred psychiatric out patients with DSM III-R panic disorder, with and without agoraphobia, 66 completed a six week placebo-controlled trial of lofepramine versus clomipramine and 57 survivors were followed up for 6 months." | 5.07 | The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. ( Brophy, J; Fahy, TJ; O'Rourke, D; Schazmann, W; Sciascia, S, 1992) |
| "Seventeen outpatients with panic anxiety and agoraphobia were treated with a low, flexible dose of clomipramine in an 8-week open trial." | 5.06 | Panic attacks and agoraphobia: low dose clomipramine treatment. ( Codner, S; Cohen, L; Gladic, D; Gloger, S; Grunhaus, L; O'Ryan, F, 1989) |
| "A double-blind comparative study of clomipramine and fluvoxamine was performed in 50 patients suffering from anxiety disorders (DSM-III)." | 5.06 | Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. ( den Boer, JA; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "The efficacy of clomipramine hydrochloride in the treatment of agoraphobia was investigated in an eight-week placebo-controlled double-blind study." | 5.06 | Clomipramine treatment of agoraphobic women. An eight-week controlled trial. ( Johnston, DG; Troyer, IE; Whitsett, SF, 1988) |
| "A double-blind placebo-controlled study of 5-HTP and clomipramine was carried out on 45 patients suffering from anxiety disorders (DSM-III)." | 5.06 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "Clomipramine (25-150 mg/day) was given in a 2-month open clinical trial to patients with DSM-III defined panic disorder (N = 8) or agoraphobia with panic attacks (N = 12); 6 of these patients were found to have MVP." | 5.05 | Clomipramine treatment for panic attacks in patients with mitral valve prolapse. ( Birmacher, B; Gloger, S; Grunhaus, L, 1984) |
| "A multi-centre, double-blind trial was carried out in general practice to compare the effectiveness and tolerability of clomipramine and diazepam in patients with agoraphobia or social phobia." | 5.05 | Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. ( Allsopp, LF; Cooper, GL; Poole, PH, 1984) |
| "A case is presented of a patient with severe panic disorder and agoraphobia in whom initial treatment with clomipramine resulted in complete elimination of panic attacks, with no improvement in agoraphobic avoidance." | 3.68 | Differential drug response of panic and agoraphobic avoidance in a case of panic disorder. ( Klein, E; Metz, L, 1990) |
| "In a large, open, multicentre trial, conducted in general practice, 765 patients suffering from agoraphobia or social phobias were treated with clomipramine (Anafranil, Geigy Pharmaceuticals)." | 3.65 | A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. ( Beaumont, G, 1977) |
| "Clomipramine was prescribed in weekly increments to a maximum of 300 mg per day, with a mean dosage at week 8 of 94." | 2.68 | Clomipramine treatment and behaviour therapy with agoraphobic women. ( Dalby, JT; Johnston, DG; Troyer, IE; Whitsett, SF, 1995) |
| "This study investigated the chronic use (6." | 1.31 | Memory performance in panic disorder patients after chronic use of clomipramine. ( Artes, R; de Carvalho, SC; Gorenstein, C; Marcourakis, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (40.63) | 18.7374 |
| 1990's | 14 (43.75) | 18.2507 |
| 2000's | 4 (12.50) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marazziti, D | 1 |
| Carlini, M | 1 |
| Dell'Osso, L | 1 |
| de Carvalho, SC | 1 |
| Marcourakis, T | 1 |
| Artes, R | 1 |
| Gorenstein, C | 2 |
| Broocks, A | 4 |
| Meyer, T | 4 |
| Opitz, M | 1 |
| Bartmann, U | 3 |
| Hillmer-Vogel, U | 4 |
| George, A | 3 |
| Pekrun, G | 3 |
| Wedekind, D | 1 |
| Rüther, E | 4 |
| Bandelow, B | 4 |
| Telch, MJ | 1 |
| Tearnan, BH | 1 |
| Taylor, CB | 1 |
| Cobb, J | 1 |
| Grunhaus, L | 3 |
| Gloger, S | 3 |
| Birmacher, B | 2 |
| Allsopp, LF | 1 |
| Cooper, GL | 1 |
| Poole, PH | 1 |
| Pecknold, JC | 1 |
| McClure, DJ | 1 |
| Appeltauer, L | 1 |
| Allan, T | 1 |
| Wrzesinski, L | 1 |
| Pohl, R | 1 |
| Berchou, R | 1 |
| Rainey, JM | 1 |
| Troudart, T | 1 |
| Johnston, DG | 2 |
| Troyer, IE | 2 |
| Whitsett, SF | 2 |
| Dalby, JT | 1 |
| Hoffart, A | 1 |
| Due-Madsen, J | 1 |
| Lande, B | 1 |
| Gude, T | 1 |
| Bille, H | 1 |
| Torgersen, S | 1 |
| Bakish, D | 1 |
| Saxena, BM | 1 |
| Bowen, R | 1 |
| D'Souza, J | 1 |
| Phillips, KA | 1 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Pope, HG | 1 |
| Hudson, JI | 1 |
| Ito, LM | 1 |
| Gentil, V | 2 |
| Miyakawa, E | 1 |
| Klein, DF | 2 |
| Ross, DC | 1 |
| Papp, LA | 1 |
| Schneier, FR | 1 |
| Fyer, AJ | 1 |
| Leibowitz, MR | 1 |
| Gorman, JM | 1 |
| Coplan, JD | 1 |
| Campeas, R | 1 |
| Fallon, BA | 1 |
| Bakker, A | 1 |
| van Dyck, R | 1 |
| Spinhoven, P | 1 |
| van Balkom, AJ | 1 |
| Toni, C | 1 |
| Perugi, G | 1 |
| Frare, F | 1 |
| Mata, B | 1 |
| Vitale, B | 1 |
| Mengali, F | 1 |
| Recchia, M | 1 |
| Serra, G | 1 |
| Akiskal, HS | 1 |
| Pralle, L | 1 |
| Gringras, M | 1 |
| Beaumont, G | 1 |
| Fahy, TJ | 1 |
| O'Rourke, D | 1 |
| Brophy, J | 1 |
| Schazmann, W | 1 |
| Sciascia, S | 1 |
| Vallada, HP | 1 |
| Westberg, P | 1 |
| Modigh, K | 1 |
| Lisjö, P | 1 |
| Eriksson, E | 1 |
| Klein, E | 1 |
| Metz, L | 1 |
| Gladic, D | 1 |
| O'Ryan, F | 1 |
| Cohen, L | 1 |
| Codner, S | 1 |
| den Boer, JA | 1 |
| Westenberg, HG | 2 |
| Kamerbeek, WD | 2 |
| Verhoeven, WM | 2 |
| Kahn, RS | 2 |
| Gispen-de Wied, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Pre- and Post-Synaptic Dopamine Function in Developmental Stuttering Using 11C-Raclopride and Positron Emission Tomography[NCT00024960] | 12 participants (Actual) | Observational | 2001-10-03 | Completed | |||
| Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study[NCT02843451] | Phase 2 | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to Focus on other studies) | ||
| A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder[NCT00540098] | Phase 4 | 75 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for clomipramine and Agoraphobia
| Article | Year |
|---|---|
Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Cognit | 2012 |
Antidepressant medication in the treatment of agoraphobia: a critical review.
Topics: Agoraphobia; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior Therapy; Clomipramine | 1983 |
Behaviour therapy in phobic and obsessional disorders.
Topics: Agoraphobia; Arousal; Behavior Therapy; Clomipramine; Cognition; Combined Modality Therapy; Desensit | 1983 |
19 trials available for clomipramine and Agoraphobia
| Article | Year |
|---|---|
5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
Topics: Adolescent; Adult; Agoraphobia; Body Temperature; Clomipramine; Combined Modality Therapy; Double-Bl | 2003 |
Clomipramine treatment for panic attacks in patients with mitral valve prolapse.
Topics: Age Factors; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Clomipramine; Fear; Female; H | 1984 |
Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice.
Topics: Adolescent; Adult; Aged; Agoraphobia; Clinical Trials as Topic; Clomipramine; Diazepam; Double-Blind | 1984 |
Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients?
Topics: Adult; Agoraphobia; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Drug Synergism; Dru | 1982 |
Clomipramine treatment and behaviour therapy with agoraphobic women.
Topics: Adult; Agoraphobia; Analysis of Variance; Behavior Therapy; Clomipramine; Combined Modality Therapy; | 1995 |
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy.
Topics: Adult; Agoraphobia; Behavior Therapy; Clomipramine; Combined Modality Therapy; Double-Blind Method; | 1993 |
Reversible monoamine oxidase-A inhibitors in panic disorder.
Topics: Agoraphobia; Clomipramine; Double-Blind Method; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibit | 1993 |
Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Imip | 1995 |
Clomipramine treatment of panic disorder: pros and cons.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Comorbidity; Drug Administ | 1997 |
Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder.
Topics: Adult; Agoraphobia; Bias; Clomipramine; Comorbidity; Exercise; Female; Humans; Male; Outcome Assessm | 1998 |
Endurance training in panic patients: spiroergometric and clinical effects.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Exercise Therapy; Female; Humans | 1998 |
Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
Topics: Adolescent; Adult; Aged; Agoraphobia; Clomipramine; Cognitive Behavioral Therapy; Comorbidity; Doubl | 1999 |
A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents; Clomipramine; Demography; Female; Humans; Imipramin | 2000 |
The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Combined Modality Therapy; Double-Blind | 2000 |
The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial.
Topics: Adult; Agoraphobia; Behavior Therapy; Clomipramine; Combined Modality Therapy; Female; Humans; Lofep | 1992 |
Panic attacks and agoraphobia: low dose clomipramine treatment.
Topics: Adolescent; Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Clomipramine; Depressiv | 1989 |
Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine.
Topics: Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Clomipramine; Double-Blind Method; | 1987 |
Clomipramine treatment of agoraphobic women. An eight-week controlled trial.
Topics: Adult; Agoraphobia; Clinical Trials as Topic; Clomipramine; Double-Blind Method; Drug Administration | 1988 |
Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.
Topics: 5-Hydroxytryptophan; Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Clomipramine; | 1987 |
10 other studies available for clomipramine and Agoraphobia
| Article | Year |
|---|---|
Memory performance in panic disorder patients after chronic use of clomipramine.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Chronic Disease; Clomipramine; Female; Humans; | 2002 |
Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Diazepam; Double-Blind Method; Humans; | 1982 |
Treatment of spontaneous panic attacks with chlomipramine.
Topics: Adult; Agoraphobia; Anxiety Disorders; Clomipramine; Female; Humans; Male; Middle Aged; Phobic Disor | 1981 |
Body dysmorphic disorder: 30 cases of imagined ugliness.
Topics: Adolescent; Adult; Age Factors; Aged; Agoraphobia; Anxiety Disorders; Body Image; Clomipramine; Delu | 1993 |
Re: Clomipramine treatment and behaviour therapy with agoraphobic women.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Behavior Therapy; Clomipramine; Combined Modality The | 1997 |
An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice.
Topics: Adult; Agoraphobia; Clomipramine; Dibenzazepines; Female; Humans; Male; Obsessive-Compulsive Disorde | 1977 |
A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders.
Topics: Adolescent; Adult; Aged; Agoraphobia; Clomipramine; Dibenzazepines; Female; Humans; Male; Marriage; | 1977 |
Musical hallucinations triggered by clomipramine?
Topics: Aged; Agoraphobia; Clomipramine; Depressive Disorder; Female; Hallucinations; Humans; Music | 1991 |
Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients.
Topics: Adult; Agoraphobia; Clomipramine; Dexamethasone; Diagnosis, Differential; Female; Humans; Hydrocorti | 1991 |
Differential drug response of panic and agoraphobic avoidance in a case of panic disorder.
Topics: Adult; Agoraphobia; Arousal; Clomipramine; Drug Therapy, Combination; Fear; Humans; Male; Panic; Phe | 1990 |